Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) ...

G-CSF Limitations: These agents essentially overstimulate a bone marrow that is already damaged by chemotherapy. Furthermore, while they address neutrophils, they do not mitigate damage to platelets ...

A small cell lung cancer (SCLC) misdiagnosis is possible. This can occur because of challenges during the diagnostic tests and because SCLC may share symptoms and causes similar to other conditions.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ...

Filippo Beleggia, MD, PhD, didn’t believe his own data. As a postdoctoral researcher, he spent years in the laboratory of Christian Reinhardt, MD, PhD, at the University Hospital Cologne, Cologne, ...

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

LEMS is an autoimmune disorder linked to SCLC, causing muscle weakness and autonomic dysfunction due to presynaptic calcium channel antibodies. Differentiation from myasthenia gravis involves ...